Vividion Therapeutics and Bayer Partnership Aims to Further Strengthen Oncology Pipeline With Solid Tumor Inhibitor June 11, 2025
First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors June 10, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
European Commission Approves SC Formulation of Opdivo Across Multiple Solid Tumor Indications June 3, 2025
BioNTech and BMS to Co-Develop and Co-Commercialize BNT327 for Multiple Solid Tumor Types June 3, 2025
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies June 3, 2025
Lumanity and Parker Institute for Cancer Immunotherapy (PICI) Announce Partnership to Accelerate Immunotherapy Innovation June 3, 2025
FDA clears IND application for ERAS-4001 for the treatment of patients with KRAS-mutant (KRASm) solid tumors June 3, 2025
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib May 27, 2025
Orionis Biosciences and Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer May 27, 2025
First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors May 27, 2025
OSE Immunotherapeutics, Inside Therapeutics, and Angers-based MiNT Laboratory to develop mRNA therapeutics and accelerate nanodrug development May 27, 2025
Helix BioPharma Secures Pre-IND Candidates LEUMUNA™ and GEMCEDA™ in Strategic Acquisition from the Laevoroc Group May 27, 2025
Monotherapy and combo arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combo to be investigated May 27, 2025
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 In Combination with KEYTRUDA May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline May 21, 2025
AbbVie and ADARx Pharmaceuticals to Develop Next-Gen siRNA Therapies Across Multiple Therapeutic Areas May 21, 2025
